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Cognitive deﬁcits in individuals with schizophrenia (SCZ) are considered core symptoms
of this disorder, and can manifest at the prodromal stage. Antipsychotics ameliorate
positive symptoms but only modestly improve cognitive symptoms.The lack of treatments
that improve cognitive abilities currently represents a major obstacle in developing more
effective therapeutic strategies for this debilitating disorder. While D4 receptor (D4R)-
speciﬁc antagonists are ineffective in the treatment of positive symptoms, animal studies
suggest that D4R drugs can improve cognitive deﬁcits. Moreover, recent work from
our group suggests that D4Rs synergize with the neuregulin/ErbB4 signaling pathway,
genetically identiﬁed as risk factors for SCZ, in parvalbumin (PV)-expressing interneurons
to modulate gamma oscillations. These high-frequency network oscillations correlate with
attention and increase during cognitive tasks in healthy subjects, and this correlation is
attenuated in affected individuals. This ﬁnding, along with other observations indicating
impaired GABAergic function, has led to the idea that abnormal neural activity in the
prefrontal cortex (PFC) in individuals with SCZ reﬂects a perturbation in the balance of
excitation and inhibition. Here we review the current state of knowledge of D4R functions
in the PFC and hippocampus, two major brain areas implicated in SCZ. Special emphasis
is given to studies focusing on the potential role of D4Rs in modulating GABAergic
transmission and to an emerging concept of a close synergistic relationship between
dopamine/D4R and neuregulin/ErbB4 signaling pathways that tunes the activity of PV
interneurons to regulate gamma frequency network oscillations and potentially cognitive
processes.
Keywords: dopamine, D4 receptor, gamma oscillations, parvalbumin, fast-spiking interneurons, prefrontal cortex,
schizophrenia, ADHD
INTRODUCTION
Schizophrenia (SCZ) is characterized by three distinct symptom
clusters – positive, negative, and cognitive. Historically, positive
symptoms such as hallucinations and delusions have received the
most attention, and are often improved by typical and atypical
antipsychotics. By contrast, negative symptoms such as social
withdrawal, lack of motivation, impaired social interactions, and
cognitive impairments including deﬁcits in attention, working
memory, and executive function are refractory to antipsychotics.
The intractability of cognitive symptoms has been amajor obstacle
in the development of more effective therapies for SCZ, especially
in light of epidemiological ﬁndings indicating that the severity
of cognitive symptoms is more predictive of long-term prognosis
than positive symptoms (Green, 1996), and that cognitive impair-
ments are already present at the prodromal stage (Reichenberg
et al., 2002).
Cognitive impairments may arise from altered activity in the
prefrontal cortex (PFC). Imaging studies suggest hypofunction of
the PFC and reduced signal-to-noise ratios during cognitive tasks
in schizophrenic patients (Winterer and Weinberger, 2004; Tost
et al., 2005). Local oscillatory network activity in cortical areas,
in particular gamma-band rhythms (30–80 Hz), correlate with
working memory and selective attention (Womelsdorf and Fries,
2007; Benchenane et al., 2011), and higher cognitive demands
correlate with increased gamma power and coherence across dif-
ferent cortical areas (Cho et al., 2006; Basar-Eroglu et al., 2007).
Numerous studies have shown that basal, evoked, and induced
gamma oscillations are altered in SCZ patients (Herrmann and
Demiralp, 2005; Uhlhaas and Singer, 2010). Most of these studies
focused on evoked oscillations in sensory cortices, in particular
the auditory cortex for its prominent role in auditory hallucina-
tions. Patients with SCZ fail to increase gamma oscillation power
in the PFC in response to increased cognitive demands, suggesting
reduced signal-to-noise (Cho et al., 2006). Gamma oscillations are
an inherent property of recurrent networks of interneurons and
pyramidal neurons, and arise by the synchronization of pyrami-
dal neuron output by fast-spiking (FS) basket cell and chandelier
interneurons expressing the Ca2+ binding protein parvalbumin
(PV). The central role of PV-expressing interneurons for the
generation of gamma rhythms has recently been demonstrated
using optogenetic techniques in vivo (Cardin et al., 2009; Sohal
et al., 2009). Moreover, numerous postmortem studies in persons
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with SCZ have shown changes in PV interneurons, in particular
decreases in mRNA and protein expression of GAD67 (glutamic
acid decarboxylase 67 kD) and PV itself (Lewis et al., 2011), con-
sistent with the notion of perturbed maturation of inhibitory PFC
circuits during adolescence (Benes and Berretta, 2001; Beneyto
and Lewis, 2011; Sullivan and O’Donnell, 2012).
It was initially thought that the dopamine (DA) system was
generally overactive in SCZ because DA D2-type receptor antago-
nizing antipsychotic medications mitigated many observed symp-
toms. However, this original DA hypothesis has evolved over
the years to account for evidence from imaging, genetic and
metabolic imaging studies more consistent with hypoactivity of
frontal cortical circuits in SCZ, hypoactivity of the mesoprefrontal
DA system and hyperactivity of mesostriatal and mesonigral DA
systems (reviewed in Simpson et al., 2010). While the importance
of dopaminergic modulation of the PFC for proper cognitive
functions is well supported by experimental evidence from non-
human primates and rodents (Goldman-Rakic, 1995; Robbins
and Arnsten, 2009), how altered DA activity contributes to PFC
hypofunction in SCZ is not understood. Moreover, given its impli-
cation in attention and working memory, surprisingly little is
known about the possible role of DA signaling in the regulation of
oscillatory activity in the PFC and hippocampus, another major
allocortical structure implicated in SCZ (Harrison, 2004).
Here we review the current state of research into the role of
DA in the modulation of network rhythms in the cortex, partic-
ularly the PFC and hippocampus, as new evidence emerges that
DA signaling is potently involved in regulating theta and gamma
oscillations. A main focus of the review is the D4 receptor (D4R),
considered a major D2-type receptor in the forebrain and promi-
nently expressed in PV-expressing interneurons. Recent studies
have shown that DA signaling via D4R, in a close and synergis-
tic relationship with the neuregulin 1 (NRG-1)/ErbB4 signaling
pathway, itself genetically implicated in SCZ, modulates gamma
rhythms in the hippocampus (Andersson et al., 2012b). Taken
together with the genetic association of the 7-repeat (7R) vari-
ant of the human DRD4 gene with increased risk for attention
deﬁcit hyperactivity disorder (ADHD) and altered gamma-band
responses (Demiralp et al., 2007; Gizer et al., 2009), these ﬁndings
should renew interest in the D4R and its possible contribution to
synchronization of PFC networks during cognitive tasks.
FAST-SPIKING INTERNEURONS AND GAMMA OSCILLATIONS
Gamma oscillations are generated through recurrent networks
of FS interneurons interconnected by chemical and electrical
synapses (for reviews, see Bartos et al., 2007; Colgin, 2011;
Whittington et al., 2011; Buzsaki and Wang, 2012). Most FS
interneurons are PV-expressing basket cells that form perisomatic
connections with multiple pyramidal neurons, faithfully release
GABA (gamma-aminobutyric acid) in response to depolarization
(Hefft and Jonas, 2005), and discharge action potentials on almost
every gamma cycle (Gloveli et al., 2005). Together, these properties
make them perfectly suited to entrain pyramidal neurons. In fact,
using in vivo optogenetic stimulation, depolarizing PV-expressing
interneurons increased gamma power, whereas hyperpolarizing
PV-expressing interneurons decreased gamma power (Sohal et al.,
2009). Moreover, work in the somatosensory cortex suggests that
gamma oscillations can be more effectively induced in vivo by 40-
Hz optogenetic stimulation of PV-expressing interneurons than
of pyramidal neurons (Cardin et al., 2009), although optogenetic
depolarization of pyramidal neurons has been shown to generate
gamma oscillations in vivo in the somatosensory cortex (Adesnik
and Scanziani, 2010) and in slices from the medial PFC (Yizhar
et al., 2011) as well. Notably, optogenetic depolarization of both
PV-positive and pyramidal neurons generate gamma synchrony
even when stimulated non-rhythmically, supporting the notion
that gamma oscillations are an emergent property of coupled net-
works of excitatory and inhibitory cells (Cardin et al., 2009; Yizhar
et al., 2011; for a review, see Tiesinga and Sejnowski, 2009).
EXCITATION/INHIBITION BALANCE
Proper balance of excitatory and inhibitory transmission onto
PV interneurons is essential for the generation of normal
gamma rhythms. Hippocampal slices prepared from mice with
PV interneuron-selective ablation of the GluA1 subunit of the
AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid) receptor have reduced power of kainate-induced gamma
oscillations in area CA3 (Fuchs et al., 2007). PV interneuron-
selective ablation of the GluN1 subunit of the NMDA (N-
methyl-D-aspartate) receptor resulted in elevated spontaneous
gamma rhythms in the hippocampus of awake behaving mice
(Korotkova et al., 2010), but impaired gamma rhythm induction
in the somatosensory cortex in response to optogenetic stimula-
tion (Carlen et al., 2012). Surprisingly, mice lacking GABAergic
transmission onto PV interneurons by selective ablation of δ and
γ2 subunits of the GABAA receptor have normal gamma oscilla-
tions but severe disruptions in theta oscillations and theta-gamma
coupling, suggesting that mutual inhibition of PV interneurons is
dispensable for in vivo gamma oscillations (Wulff et al., 2009).
N-methyl-D-aspartate receptors on FS interneurons have long
been considered critical for normal excitation/inhibition balance
in cortical microcircuits and are at the center of the glutamate
hypofunction theory of SCZ (Lisman et al., 2008; Nakazawa et al.,
2012). This hypothesis is based on ﬁndings that dissociative anes-
thetics that antagonize NMDA receptors such as ketamine and
phencyclidine (PCP) elicit psychotic symptoms in normal indi-
viduals similar to those found in SCZ subjects and exacerbate
psychosis in patients (Kantrowitz and Javitt, 2012). As discussed
above, compelling evidence from gene targeting studies implicates
NMDA receptors in gamma synchrony. However, a recent study
comparing postnatal vs. adult ablation of the GluN1 subunit sug-
gests that NMDA receptors on FS interneurons might be more
important for the proper maturation of cortical circuits and the
emergence of gamma oscillation during development than for a
direct contribution to synaptic processes underlying gamma oscil-
lation induction or propagation (Belforte et al., 2010; Korotkova
et al., 2010). Consistent with this idea, electrophysiological stud-
ies in wild-type mice show that excitatory postsynaptic potentials
(EPSPs) on FS interneurons have large contributions from NMDA
receptors in juveniles that diminish during maturation (Wang
and Gao, 2009; Rotaru et al., 2011). Notably, since NMDA recep-
tors have slower kinetics than AMPA receptors, the summating
properties of excitatory synapses with a large NMDA receptor
contribution could make them less suitable to support gamma
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rhythms. Therefore, excitatory drive is dominated byAMPA recep-
tors in mature FS interneurons to ensure high temporal precision
between excitation and spiking (Rotaru et al., 2011).
PHENOTYPIC ALTERATIONS OF PV INTERNEURONS IN SCZ
Postmortem studies have consistently revealed decreased levels of
GAD67 mRNA in the dorsolateral PFC (DLPFC) and hippocam-
pus of SCZ subjects, particularly in PV interneurons (for reviews,
see Benes and Berretta, 2001; Gonzalez-Burgos and Lewis, 2012).
As GAD67 synthesizes the inhibitory neurotransmitter GABA, it
seems reasonable to speculate that diminished GAD67 expression
reduces inhibitory drive, perturbs normal excitation/inhibition
balance, and thereby impairs neural synchrony. Interestingly, SCZ
subjects also have reduced PV expression in the cortex (Hashimoto
et al., 2008), a ﬁnding that has been suggested to represent a com-
pensatory response to lower GAD67 levels, as PV-deﬁcient mice
exhibit increased GABA release and kainate-induced hippocam-
pal gamma oscillations power and frequency (Vreugdenhil et al.,
2003). An alternative interpretation, based on the marked depen-
dence of the expression of both GAD67 and PV genes on neural
activity, is that reduced levels of GAD67 and PV are a consequence
of abnormally low activity of FS interneurons in SCZ subjects.
Work in rodents suggests that GAD67-mediated GABA syn-
thesis has an additional role in shaping GABAergic innervation
of cortical networks during adolescence, a period in which PV
interneuron networks mature and gamma oscillations become
prevalent (Chattopadhyaya et al., 2007). Reduced GAD67 expres-
sion during adolescence could therefore conceivably cause per-
sistent changes in GABAergic innervation, resulting in perturbed
excitation/inhibition balance and dysfunctional cortical networks
in affected individuals. Lastly, it has been proposed that because
of their high metabolic demand, FS interneurons are particu-
larly vulnerable to oxidative stress during development. Consistent
with this notion, studies have identiﬁed abnormal antioxidant sys-
tems in SCZ subjects, and work in rodents has demonstrated that
exposure to oxidative stress causes loss of PV-immunoreactivity
in FS interneurons and reductions in high-frequency network
oscillations (Behrens and Sejnowski, 2009; Do et al., 2009).
GAMMA OSCILLATIONS IN SCZ
While abnormalities in neural oscillations have been identiﬁed
in essentially all frequency bands in patients with SCZ (Moran
and Hong, 2011), gamma-band activity is particularly affected
and might represent an endophenotypic biomarker of its etiology
(Uhlhaas and Singer, 2012). This notion is based on reports of
high heritability of altered auditory and visual steady-state evoked
potentials (SSEPs) in affected individuals and their ﬁrst-degree
relatives (for example, Hall et al., 2011), and on studies ﬁnding
that perturbations in gamma-band responses present early in the
course of the disorder and are independent of medication status
(Gallinat et al., 2004; Symond et al., 2005; Haenschel et al., 2009;
Minzenberg et al., 2010).
In general, high-frequency beta and gamma oscillations syn-
chronize local networks, while low-frequency delta, theta, and
alpha oscillations establish synchronization over longer distances
(von Stein and Sarnthein, 2000). Similarly, gamma oscillations
between the PFC and cortical sensory areas mediate attention by
enhancing the neuronal representation of attended sensory input,
while theta oscillations between the PFC and hippocampus medi-
ate working and long-term memory (Benchenane et al., 2011). A
given neuron may participate in several of these frequencies at
any given time, and measures of cross-frequency coupling indi-
cate how well one frequency is embedded in another. Evidence of
abnormal neural oscillations in SCZ comes from a large number of
clinical studies primarily using electroencephalography (EEG) and
magnetoencephalography (MEG). These studies revealed changes
in sensory-evoked gamma oscillations, oscillations that correlate
with propensity for hallucinations, and abnormal modulation of
neural oscillations during cognitive tasks.
In “bottom-up” approaches, patients have been shown to have
trouble generating,maintaining, and propagating SSEPs entrained
by stimuli presented at gamma-band frequency, with impair-
ments in both phase-locking and amplitude. Similarly,“top-down”
perceptual processing paradigms such as auditory oddball tasks,
sustained tones, speech sounds, and button-press tasks mostly
revealed impairments in evoked gamma power (Haig et al., 2000)
and synchrony (for an excellent review on both approaches, see
Uhlhaas and Singer, 2010). Lastly, evoked oscillations triggered by
direct transcranial magnetic stimulation are markedly reduced in
patients with SCZ and are conﬁned to the stimulated brain region,
whereas gamma oscillations propagate to neighboring cortical
regions in healthy controls (Ferrarelli et al., 2008).
Apart from lower stimuli-evoked gamma oscillations, affected
individuals also show reduced high-frequency activity at rest (Rut-
ter et al., 2009). Interestingly, they also have a greater number of
uncorrelated gamma oscillations at rest, especially between the
PFC and other cortical areas, resulting in reduced coordination
of cortical activity (Yeragani et al., 2006; Salvador et al., 2010;
Kikuchi et al., 2011). The variety of concurrent but uncorrelated
oscillations in various areas could be described as “noise” because
they potentially mask salient signals evoked from sensory cortices.
Gamma oscillation signal-to-noise ratios are reduced in SCZ dur-
ing cortical information processing, due to elevated spontaneous
activity and reduced evoked responses (for example, Winterer
et al., 2000; reviewed in Gandal et al., 2012).
Task demands with a strong cognitive component have also
been used to reveal gamma deﬁcits in SCZ patients. For exam-
ple, patients with SCZ have abnormal oscillations during lexical
encoding (Xu et al., 2013), and do not display typical increases
in gamma activity during mental arithmetic (Kissler et al., 2000).
During working memory tasks, healthy controls increase gamma
oscillations in frontal cortical areas as the task demands increase.
However, SCZ patients show maximal gamma oscillatory activ-
ity for simple working memory tasks as well as difﬁcult ones
(Cho et al., 2006; Basar-Eroglu et al., 2007). Moreover, gamma
power during encoding andmaintenance positively correlateswith
performance in these tasks, and SCZ patients show deﬁcits in
producing this delay-period gamma oscillation (Cho et al., 2006;
Haenschel et al., 2009; Minzenberg et al., 2010).
Several studies show that increased high-frequency oscilla-
tions in primary sensory cortices correlate with the propensity for
auditory hallucinations in SCZ patients, even when subjects are
not actively hallucinating (Baldeweg et al., 1998; Lee et al., 2006;
Mulert et al., 2011). An increased tendency for neural circuits to
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enter states of high-frequency synchronization has been suggested
to reﬂect hyperexcitability in sensory cortices (Spencer et al., 2009).
DOPAMINE’S ROLE IN NEURAL OSCILLATIONS AND
COGNITION
The importance of DA neurotransmission for attention and nor-
mal cognitive function has long been recognized. Deﬁciencies
in mesoprefrontal dopaminergic circuits in humans are associ-
ated with major psychiatric disorders such as SCZ, ADHD, and
addiction (Winterer and Weinberger, 2004; del Campo et al.,
2011; Goldstein and Volkow, 2011). In rodents and non-human
primates, DA modulates PFC neuron activity during cognitive
tasks and motivational behaviors (Goldman-Rakic, 1995; Grace
et al., 2007; Robbins and Arnsten, 2009), and pharmacological
lesions of dopaminergic projections to the PFC greatly impair
working memory (Brozoski et al., 1979). DA effects on cogni-
tive performance exhibit an inverted U-shaped dose–response
curve (Sawaguchi and Goldman-Rakic, 1994; Vijayraghavan et al.,
2007). In cortical areas, extracellular DA is cleared mostly by
enzymatic inactivation catalyzed by the product of the catechol-O-
methyltransferase gene (COMT). A functional variation exists in
the human population (Val158Met) in which theVal allele renders
the enzyme signiﬁcantly more active than the Met allele, thereby
inactivating extracellular DA more rapidly. Homozygous carriers
of the Val allele are therefore believed to have lower prefrontal DA
levels and indeed show reduced performance in working memory
and executive function tasks (Goldberg et al., 2003). Moreover,
amphetamine improves prefrontal signal-to-noise ratio during
a working memory task assayed by fMRI (functional magnetic
resonance imaging) in Val homozygotes but decreases signal-to-
noise in Met homozygotes, consistent with an inverted U-shaped
dose–response curve (Mattay et al., 2003).
DA AND GAMMA OSCILLATIONS
While both DA and network oscillations have long been impli-
cated in cognitive function, the interactions between DA and
neural network activity in normal and pathological conditions
have remained poorly understood. From a historical perspective
this is not entirely surprising, given that DA receptor-targeting
ﬁrst-generation and atypical antipsychotics have proven mostly
ineffective in improving cognitive deﬁcits in SCZ patients. How-
ever, the need for a better understanding of DA effects on neural
oscillations has been acknowledged (Whittington et al., 2011; Gan-
dal et al., 2012), and a number of clinical and preclinical studies
have begun to explore these relationships. While there is as yet
no uniﬁed view of the effects of DA on neural networks owing
at least in part to methodological and conceptual differences (in
vitro vs. in vivo recordings, knock-out models vs. acute treat-
ments, general DA signaling vs. selective modulation of distinct
DA receptor subtypes), recent studies point to an important role
of DA in network dynamics. Available data from human EEG
studies suggests that DA increases the power of neural oscillations
in the PFC, but has little effect on their induction or frequency.
Carriers of polymorphisms in the DA transporter gene DAT1 that
prolong event-related increases in DA, show an increase in evoked
gamma power in response to target stimuli (Demiralp et al., 2007).
In healthy subjects, the ﬁrst-generation antipsychotic haloperidol
reduces gamma power in response to attended stimuli (Ahveni-
nen et al., 2000), although it is unclear to what extent this effect is
attributable to D2-type receptor inhibition or blockade of other
haloperidol targets such as NMDA receptors.
Dopamine has been suggested to affect cognitive processes
by modulating signal-to-noise ratios in PFC microcircuits (Win-
terer and Weinberger, 2004). Supporting indirect evidence comes
from studies on working memory performance in which D1-type
DA receptors optimize signal-to-noise ratio in prefrontal neural
representations of non-human primates (Goldman-Rakic, 1995;
Williams and Goldman-Rakic, 1995; Vijayraghavan et al., 2007).
Interestingly, carriers of the DRD4.7 allele, a subsensitive vari-
ant of the D4R (see Identiﬁcation of the D4R), exhibit similar
increases in auditory cortex gamma power to both standard and
target stimuli in an auditory target detection paradigm, suggestive
of a reduced signal-to-noise ratio (Demiralp et al., 2007).
Genetic mouse models and acute pharmacological treatments
have been employed to study the effects of alteredDA transmission
on gamma and theta oscillations in the hippocampus and PFC.
Hyperdopaminergic DAT1 knock-out mice show increased hip-
pocampal (but not cortical) gamma power, and enhanced gamma
phase synchrony between the hippocampus and the PFC during
novelty-induced exploration (Dzirasa et al., 2006, 2009). However,
acute elevations of DA levels by amphetamine, apomorphine, or
methamphetamine treatments hadno signiﬁcant effect onbaseline
or auditory-evoked gamma in the rodent cortex and hippocampus
(Ma and Leung, 2000; Pinault, 2008; Ehrlichman et al., 2009).
Electrophysiological studies in which gamma oscillations were
induced electrically or pharmacologically in rodent brain slices
have yielded varying results regarding the involvement of the DA
system. Ketamine-induced gamma oscillation power in the rat
PFC was reduced by clozapine and haloperidol (Jones et al., 2012).
Likewise, in hippocampal area CA1, DA increased the power and
duration of stimulation-induced gamma oscillations (Wójtowicz
et al., 2009) but decreased the power and duration of carbachol-
induced oscillations (Weiss et al., 2003). However, kainate-induced
gamma oscillations were found to either be decreased in CA1
and CA3 (Wójtowicz et al., 2009) or unchanged in CA3 (Ander-
sson et al., 2012b). These variances might be partly explained by
differences in the mechanisms underlying each type of oscillation.
Pharmacological analysis of the involvement of different types
of DA receptors in pharmacologically induced in vitro gamma
oscillations has revealed an unexpected wealth of targets and
effects. The selective D4R agonist PD168077 augmented gamma
oscillation power in CA3 (Andersson et al., 2012b); this ﬁnding
will be discussed in more detail in Section “D4R and Gamma
Oscillations.” Conversely, clozapine, an atypical antipsychotic
with moderate selectivity for D4R and 5-HT3 receptors, and
haloperidol reduced the amplitude and increased the band-
width of acetylcholine-induced gamma oscillations in CA3. The
effects of clozapine were attributed to inhibition of 5-HT3 sero-
tonergic receptors based on the ability of the 5-HT3 agonist
m-chlorophenylbiguanide to augment gamma oscillations; the
same study also reported that direct stimulation of the D3R by the
preferentially selective agonist PD128907 inhibited gammaoscilla-
tions (Schulz et al., 2012). Clozapine also suppressed spontaneous
synchronized pyramidal network activity in layer V of the PFC
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(Gao, 2007). Lastly, activation of D1-type DA receptors decreased
carbachol-induced gamma oscillation power (Weiss et al., 2003).
Taken together, the interpretation of DA effects on oscillations are
complex and likely depend on multiple factors including the brain
area investigated,mechanisms of gammaoscillation induction and
DA receptor pharmacology.
There is also evidence for an involvement of DA in theta oscil-
lations. Theta frequencies frequently bind distributed networks
oscillating at gamma frequency and predominate in the hippo-
campus during active behavior. Depleting DA in the hippocampus
decreases theta activity (Nakagawa et al., 2000), while injecting DA
or apomorphine into the medial septum increases hippocampal
theta oscillations (Miura et al., 1987). Moreover, direct infusion
of DA into the PFC of anesthetized rats increases theta oscillation
coherence between the PFC and the hippocampus (Benchenane
et al., 2010).
MODULATION OF FS INTERNEURON PROPERTIES BY DA
Three key determinants of the power and frequency of gamma
oscillations are (1) themagnitude and (2) kinetics of synaptic inhi-
bitionbetween interneurons, and (3) thedriving excitatory current
onto interneurons (Traub et al., 1996). Non-selective stimulation
of DA receptors by exogenous DA appears not to change the elec-
trical coupling of interneurons through gap junctions (Towers
and Hestrin, 2008). However, selective activation of D1-type or
D4 receptors reduces coupling (Hampson et al., 1992; Onn and
Grace, 1994; Li et al., 2013) while activation of D2-type receptors
increases coupling (Onn and Grace, 1994), suggesting oppos-
ing effects of different DA receptor types. Moreover, DA acting
through D1-type receptors decreases the amplitude of inhibitory
postsynaptic currents (IPSCs) in FS interneurons (Towers and
Hestrin, 2008). DA also changes the intrinsic properties of FS
interneurons by increasing their evoked ﬁring rate in vivo (Tseng
et al., 2006), and in vitro (Zhou and Hablitz, 1999; Gorelova et al.,
2002; Gao et al., 2003; Kröner et al., 2007; Trantham-Davidson
et al., 2008; but see Tierney et al., 2008).
By simultaneously reducing spontaneous ﬁring and increasing
evoked ﬁring in PV interneurons, DA augments temporal preci-
sion and thereby sharpens the spike timing of FS interneurons
(Gao et al., 2003; Tierney et al., 2008). Furthermore, D1-type
and D2-type receptors increase the amplitude and kinetics of
the h-current in layer I PFC interneurons (Wu and Hablitz,
2005). Because blockade of the h-current, an inwardly recti-
fying hyperpolarization-activated non-selective cation current,
causes intrinsic changes in the frequency and power of many
cortical oscillation frequencies (Kramer et al., 2008), it seems
plausible that increases in the h-current also affect oscillations.
Likewise, DA activation reduces potassium currents, thereby
increasing the probability of repetitive ﬁring, and potentially
changing oscillatory patterns (Gorelova et al., 2002; Schreiber
et al., 2004). Computational modeling suggests that D4Rs may
modify potassium currents to increase gamma power (Kuznetsova
and Deth, 2008), although experimental veriﬁcation is still
pending. We will discuss D4R effects on synaptic and intrin-
sic properties and on gamma oscillations in more detail in
Sections “D4R Signaling Partnerships” and “D4R and Gamma
Oscillations.”
ROLE OF DA IN THE MATURATION OF FS INTERNEURONS DURING
ADOLESCENCE
Prefrontal cortex circuits ﬁnish maturing during adolescence and
early adulthood, a period of high vulnerability to ﬁrst psychotic
episode in persons with SCZ. Maturation involves concomitant
changes in responses to DA within FS interneurons, DA recep-
tor composition in FS interneurons, and gamma-band activity
during cognitive performance. From childhood to early ado-
lescence, gamma frequency oscillations dominate most cortical
regions, and their power correlates with increases in cognitive
performance. Strikingly, gamma oscillations ebb during adoles-
cence then increase dramatically in early adulthood (Uhlhaas et al.,
2009). At the end of this period, DA exerts more control over
excitation/inhibition balance and thereby aids in the selection of
adequate behavioral responses (O’Donnell, 2010).
Dopamine receptor expression and signaling change with age
in rodents. D1Rs, D2Rs, and D4Rs increase in density in the PFC
through adolescence and then show a reduction in adult animals
(Zhang et al., 2004; Brenhouse et al., 2008; Naneix et al., 2012; but
see Tarazi and Baldessarini, 2000). Furthermore, pharmacological
blockade of D1-type receptors increases the intrinsic excitabil-
ity of FS interneurons in slices from both adult (PD > 50) and
juvenile (PD < 35) rats, while the D2-type receptor agonism
increases FS interneuron excitability in post- but not pre-pubertal
slices (Tseng andO’Donnell, 2007), thereby enhancingDA’s overall
effect on intrinsic FS interneuron excitability. Similarly, in slices
from pre-pubertal rats, co-administration of a D1-type agonist
and NMDA excites pyramidal neurons for only tens of millisec-
onds, but in adults it creates plateau depolarizations lasting several
hundred of milliseconds (Tseng and O’Donnell, 2005). Overall,
DA receptor agonists exert more precise control over both exci-
tatory and inhibitory neurons in adult animals, suggesting that
DA may modulate oscillatory network behavior more strongly
in adults.
Mature FS interneurons have faster membrane oscillations
and spikes, less adaptation, and less NMDA contribution (Okaty
et al., 2009; Belforte et al., 2010; Wang and Gao, 2010; Gold-
berg et al., 2011; Rotaru et al., 2011), and DA innervation and
signaling might play a role in the maturation of FS interneu-
rons. Treatment with DA or coculture with mesencephalic slices,
which increases available DA, accelerates PV interneuron matu-
ration in rat organotypic slices from the frontorbital cortex and
increases the density of PV-positive cells in deep cortical layers
(Porter et al., 1999; Ross and Porter, 2002). Moreover, elevation
of prenatal DA levels by intrauterine cocaine exposure increases
the ramiﬁcation of PV interneurons in the anterior cingulate, a
cortical area receiving dense dopaminergic innervation, but not
the primary visual cortex, an area that receives little dopaminergic
innervation (Wang et al., 1995). Conversely, 6-hydroxydopamine
lesions in the medial forebrain bundle cause a reduction of the
density of PV-expressing cells in the zona incerta of the dien-
cephalon without reducing the total number of cells, suggesting
that DA is required for the maintenance of a mature FS interneu-
ron phenotype (Heise and Mitrofanis, 2005). These ﬁndings are
consistent with the notion that the DA system is a critical mod-
ulator of GABAergic interneurons during postnatal maturation
of cortical connectivity (O’Donnell, 2010) and that persons with
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SCZ exhibit reduced PV and GAD67 immunoreactivity (Lewis
et al., 2011).
PROPERTIES OF THE D4 DOPAMINE RECEPTOR
IDENTIFICATION OF THE D4R
Following the cloning of the genes and cDNAs for the pro-
totypical D2R and D1R, the gene for the human D4R (gene
symbol: DRD4) was isolated in 1991 by homology cloning in
an effort to identify additional D2-related receptors (Van Tol
et al., 1991). Similar to the other D2-type receptors, it con-
tains short amino-terminal extracellular and carboxyl-terminal
intracellular tail domains, and a fairly long third-intracellular
loop. DA has the highest afﬁnity for D4R among all DA recep-
tors (Rondou et al., 2010). Moreover, the other catecholamines
epinephrine and norepinephrine bind to and activate the D4R
with submicromolar afﬁnities (Lanau et al., 1997). An outstand-
ing feature of the human D4R is its highly polymorphic nature,
owing in large part to the presence of a 48-bp variable num-
ber tandem repeat in exon III (Van Tol et al., 1992), with four
and seven repeats being the most common variants overall but
with substantial regional and ethnic differences in frequencies
(Chang et al., 1996). By contrast, most non-primate mammal
DRD4 orthologs harbor only two repeats. The repeat encodes a
proline-rich sequence located in the third intracellular loop. It
conforms to a SH3 (Src Homology 3 Domain)-binding motif
and has been implicated in receptor surface expression and inter-
actions with adapter proteins such as Nck and Grb2 (Oldenhof
et al., 1998). Using the amplitude of G protein-induced inwardly
rectifying (GIRK) potassium currents to determine receptor acti-
vation in a heterologous Xenopus oocyte expression system, DA
was shown to be more potent at the D4.2 and D4.7 recep-
tor variants than the D4.4 receptor variant (Wedemeyer et al.,
2007). Functional differences between receptor variants were also
reported for clozapine binding, stimulation of GTPγS binding
and coupling to adenylyl cyclase (Van Tol et al., 1992; Asghari
et al., 1995; Jovanovic et al., 1999; Czermak et al., 2006). Numer-
ous studies have sought to correlate polymorphic DRD4 variants
to psychiatric disorders, including association of the D4.7 variant
with increased risk for ADHD (see Pharmacological Properties
and Involvement in Psychiatric Disorders), and with the per-
sonality trait of novelty seeking (Ebstein et al., 1996), although
some failed to replicate the original ﬁndings (for example, Hawi
et al., 2000). Of particular interest to the topic of this review,
D4.7 has been linked with altered cortical auditory-evoked and
induced gamma-band responses, thereby implicating polymor-
phic D4R variants in neural oscillations (Demiralp et al., 2007;
see Pharmacological Properties and Involvement in Psychiatric
Disorders).
PHARMACOLOGICAL PROPERTIES AND INVOLVEMENT IN
PSYCHIATRIC DISORDERS
Initial pharmacological analyses indicated that clozapine has a
higher afﬁnity for the D4R than D2R, therefore D4R was proposed
to constitute the main pharmacological target of this efﬁca-
cious atypical antipsychotic (Van Tol et al., 1991). In contrast to
typical or ﬁrst-generation antipsychotics, extrapyramidal effects
are observed to a lesser extent, or not at all, in patients treated
with clozapine. While these ﬁndings generated excitement early
on, subsequent studies argued against the possible utility of D4R-
targeting drugs to treat the positive symptoms of SCZ. Most
importantly, novel, more selective D4R antagonists such as L-
745,870 and sonepiprazole were largely ineffective as neuroleptics
in clinical trials (Bristow et al., 1997; Kramer et al., 1997; Corri-
gan et al., 2004). Consistent with this, clozapine is known to target
numerous other receptor systems with low nanomolar afﬁnities,
including serotonergic (5-HT2), muscarinic, and β-adrenergic
receptors (Baldessarini and Frankenburg, 1991), and it was con-
cluded that its efﬁcacy as a neuroleptic reﬂected a much more
complex multi-target pharmacology with a signiﬁcant contri-
bution from serotonergic receptors (Meltzer and Huang, 2008).
These ﬁndings, taken together with genetic association studies
that largely failed to identify DRD4 polymorphic variants as risk
factors (Jonsson et al., 2003), and the inability to reproduce earlier
radiolabel binding studies that suggested elevated D4R expression
in SCZ subjects (Seeman et al., 1993), dampened enthusiasm to
pursue the D4R as a promising antipsychotic drug target for SCZ
(Tarazi et al., 2004).
However, the D4R soon re-emerged as a genetic risk fac-
tor for ADHD, a heterogeneous but highly heritable syndrome
characterized by a variable combination of persistent, pervasive
and developmentally inappropriate levels of inattention, hyper-
activity and impulsiveness that typically lead to poor academic
performance (American Psychiatric Association, 2000). Pertur-
bations of catecholaminergic pathways are a leading hypothesis
in ADHD, and dopaminergic drugs such as methylphenidate are
clinically efﬁcacious. Consistent with this, numerous ADHD can-
didate genes includingDRD4,DAT1,COMT,MAOA, andDBH are
integral parts of the catecholaminergic neurotransmission system.
Both case–control and family-based association studies reported
increased transmission of the polymorphic DRD4.7 variant (for
example, LaHoste et al., 1996; Rowe et al., 1998; Smalley et al.,
1998; Swanson et al., 1998) and other polymorphisms (Barr et al.,
2000; Arcos-Burgos et al., 2004) in children diagnosed with the
syndrome. Subsequentmeta-analyses supported a linkage between
the DRD4.7 allele and ADHD (for example, Faraone et al., 1999;
Maher et al., 2002).
Cognitive effects of acute D4R activation
Although D4R antagonists proved ineffective as antipsychotics,
D4R-targeting drugs have been examined in cognitive tasks in
monkeys and rodents. For the most part, D4R agonists increase
working memory performance and fear acquisition according to
an inverted U-shaped dose response curve (Bernaerts and Tirelli,
2003; Browman et al., 2005;Woolley et al., 2008; but see Nayak and
Cassaday, 2003); interestingly, D4R antagonists have paradoxical
promnesic effects at low doses (Zhang et al., 2004). Speciﬁcally,
low doses of D4R antagonists reverse working memory deﬁcits
induced by stress or chronic PCP administration in monkeys
(Jentsch and Roth, 1999; Arnsten et al., 2000). In rats, D4R antag-
onists increase DA release in the PFC (Broderick and Piercey,
1998), possibly explaining these promnesic effects according to
the inverted U-shaped dose–response curve for DA and cogni-
tion. Further supporting this idea, rats with low baseline memory
performance showed the greatest improvements in response to
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low doses of the D4R antagonist L-745,870 and impairments at
high doses, while rats with high baseline memory performance
were impaired by administration of L-745,870 at every concentra-
tion (Zhang et al., 2004). In the rat, intra-medial PFC (mPFC)
injection of L-741,741, another highly selective D4R inhibitor,
blocks the acquisition (but not expression) of fear condition-
ing and the encoding of emotional memory by mPFC neurons
(Laviolette et al., 2005). Conversely, medial PFC injection of the
D4R agonist PD168077 increases the salience of sub-threshold
foot shocks while it blocks the acquisition of fear conditioning
in response to supra-threshold foot shocks (Lauzon et al., 2009;
Tye et al., 2009). Additionally, the D4R agonists A-412997 and
PD168077 enhance memory for aversive stimuli according to an
inverted U-shaped curve (Browman et al., 2005), but have also
shown linear increases in working memory performance in a sim-
ilar procedure and a novel object recognition paradigm (Bernaerts
and Tirelli, 2003; Woolley et al., 2008). Taken together, these
results suggest that the D4R mediates memory consolidation of
both normal and emotionally salient experiences, and that the
intensity of the stimulus interacts with DA signaling through
D4Rs.
EXPRESSION IN FS PARVALBUMIN INTERNEURONS
A number of studies have found D4R mRNA and protein in PV
interneurons of both the PFC and the hippocampus. Expression
in these neurons was ﬁrst observed in the monkey by dou-
ble immunohistology using a carefully characterized polyclonal
antibody against the extracellular amino-terminus of the recep-
tor (Mrzljak et al., 1996). Immunoreactive cells were found in
PFC layers III–V and in hippocampal area CA1. In both areas,
strongly labeled PV interneurons were accompanied by lightly
labeled pyramidal neurons. This study also found intense D4R
immunoreactivity in the rodent globus pallidus (homologous to
the primate external globus pallidus, or GPe), that is made up
entirely of GABAergic projection neurons. Evidence for D4R
expression in PV interneurons also comes from a single-cell
RT-PCR study of acutely isolated rat PFC neurons (Vysokanov
et al., 1998). Moreover, reporter gene expression was detected
in PFC pyramidal neurons and interneurons, some of them
expressing PV, in mice harboring a BAC transgene in which
the green ﬂuorescent protein was expressed under the transcrip-
tional control of the Drd4 locus (Noain et al., 2006). Two groups
additionally investigated D4R expression in GABAergic interneu-
rons using double-in situ hybridization for D4R and GAD67,
and identiﬁed co-expressing cells in layer V of the monkey
PFC (de Almeida et al., 2008) and in the mouse hippocam-
pus (Andersson et al., 2012b). The latter study also employed
double-immunohistochemistry using an antibody raised against
the extracellular amino-terminus of the rat D4R (Ariano et al.,
1997) and found that the majority (71%) of D4R-expressing
neurons in areas CA1 and CA3 co-express PV and that con-
versely 21% of PV interneurons co-express D4R. In aggregate,
what emerges from all these ﬁndings is the notion that in the
PFC, both local GABAergic interneurons and pyramidal neurons
express D4R transcript and protein, while in the hippocam-
pus the evidence favors D4R expression largely in GABAergic
interneurons.
BEHAVIORAL PHENOTYPES OF MICE LACKING D4R FUNCTION
Locomotor effects
An initial behavioral analysis of mixed-background (C57Bl/6J ×
129) Drd4−/− mice revealed locomotor hypoactivity and
increased sensitivity to locomotor-stimulating effects of acute
ethanol, cocaine, and methamphetamine injections, indicative
of deﬁcits in nigrostriatal function (Rubinstein et al., 1997).
Amphetamine hypersensitivity was conﬁrmed in a subsequent
study using Drd4−/− mice congenic on the C57Bl/6J background,
and expanded to also include altered behavioral sensitization to
repeated amphetamine injections (Kruzich et al., 2004). At the
neurochemical level, Drd4−/− mice exhibit altered striatal DA
metabolism (Rubinstein et al., 1997), and lower baseline and KCl-
evoked extracellular striatal DA levels (Thomas et al., 2007). In
contrast, DA synthesis and turnover in the PFC of mutant mice
is not signiﬁcantly different (Rubinstein et al., 2001). Evidence
in favor of a role of the D4R in regulating motor activity also
comes from studies reporting that D4R antagonism restores nor-
mal locomotor activity in periadolescent rats rendered transiently
hyperactive by neonatal 6-hydroxydopamine lesions (Zhang et al.,
2001). These lesions reduce dopaminergic projections to the
forebrain and serve as a neurodevelopmental model of ADHD
with good face validity, reproducing a number of its core symp-
toms. Strikingly, 6-hydroxydopamine-mediated hyperactivity is
absent in Drd4−/− mice (Avale et al., 2004). Although these
ﬁndings strongly suggest a role for the D4R in mediating behav-
ioral responses to perturbed DA function in the striatum, it
remains unclear if these effects originate, as suggested, in a hyper-
excitable PFC or elsewhere, and what molecular and cellular
D4R-dependent processes underlie them.
Cognitive effects
The involvement of the D4R in cognitive functions, in par-
ticular avoidance behavior and emotional learning, has been
analyzed in both mutant mice as well as in acute pharmacological
paradigms (see also Cognitive Effects of Acute D4R Activation).
Dulawa et al. (1999) found that Drd4−/− mice exhibited less
novelty-seeking behavior compared to wild-type controls with-
out displaying changed anxiety. While this report concluded that
D4R deﬁciency did not affect avoidance behavior, a different study
found that Drd4−/− mice exhibited heightened anxiety in the
elevated plus maze and light/dark preference exploration tests
that was ameliorated by ethanol and the benzodiazepine mida-
zolam (Falzone et al., 2002). The fact that these anxiolytic drugs
work by increasing GABAergic transmission, taken together with
prominent D4R expression in interneurons in the PFC, striatal
DA dysregulation and increased excitability of PFC neurons from
mutant mice (Rubinstein et al., 2001), was interpreted as indica-
tive of altered PFC control of striatal DA release in Drd4−/−
mice. On the other hand, acute pharmacological inhibition of
D4R in the rat mPFC by L-745,870 injection was shown to be anx-
iolytic in the elevated plus maze and shock-probe burial test (Shah
et al., 2004). Taken together, these ﬁndings suggest that the D4R
is involved in emotional learning, but that the effects of recep-
tor interference depend on the experimental approach utilized
(acute/local/pharmacological vs. chronic/global/genetic). Consis-
tent with this notion, studies have found secondary changes in
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Drd4−/− mice, including upregulation of D1- and NMDA recep-
tor expression and increased striatal glutamate that might reﬂect
compensatory responses to a lack of D4R function in mutant mice
(Gan et al., 2004; Thomas et al., 2009).
Consistent with the notion of altered PFC function in subjects
with SCZ, micro-PET (positron emission tomography) imag-
ing experiments in Drd4−/− mice indicate reduced baseline
PFC glucose metabolism (Michaelides et al., 2010). Moreover,
methylphenidate decreases PFC glucose metabolism in normal
mice, but increases it in mutants (Michaelides et al., 2010). It
is unclear to what extent these metabolic changes are directly
linked to the lack of D4R function in these mice, or to com-
pensatory changes aforementioned. Interestingly, while Drd4
homozygous mice are normal in behavioral tests of attention
and impulsivity (Helms et al., 2008; Young et al., 2011), Drd4
heterozygous mice exhibit less response inhibition in the ﬁve
choice – continuous performance task (Young et al., 2011). This
observation is consistent with a lack of secondary neurochemical
changes in Drd4+/− mice (Thomas et al., 2007) and might there-
fore represent a true hypomorphic D4R phenotype that is not
occluded by compensatory neural adaptations observed in the full
mutants.
SYNAPTIC EFFECTS OF D4Rs
Effects on cortical microcircuits
Cellular effects of D4R signaling in neurons havemostly been stud-
ied using electrophysiological recordings in brain slices, acutely
dissociated neurons or long-term neuron cultures. Importantly,
many of the effects discussed below were observed using high con-
centrations of the D4R agonist PD168077 that may also activate
adrenergic α1A and α2C as well as serotonergic 5-HT1A recep-
tors (Moreland et al., 2005). At the local circuit level, Onn et al.
(2006) found that in PFC slices with intact synaptic connections
between axon collaterals and recorded neurons, D4R inhibition
causes complex evoked spike discharges in pyramidal neurons,
but only with intact GABAergic transmission. The authors sug-
gest that DA signaling bi-directionally regulates PFC pyramidal
neuron excitability viaD1R andD4R-dependent pathways, respec-
tively, and thatD4Rs reduce pyramidal neuron excitability through
their tonic activity by low ambient levels of DA. Consistent with
these results,Drd4−/− mice exhibit hyperexcitability of PFC pyra-
midal neurons and are more sensitive to bicuculline (Rubinstein
et al., 2001). Although these ﬁndings indicate a possible role of
D4Rs in promoting GABAergic transmission onto PFC pyramidal
neurons, acute assessments of the effects of pharmacological D4R
perturbations on GABAergic interneuron function have yielded
mixed results, possibly stemming from the use of non-speciﬁc
drugs (Gorelova et al., 2002; Gao, 2007). The possibility that D4R
effects might vary between different cortical areas has to be con-
sidered as well, as pharmacological data from the prelimbic cortex
suggest that D4Rs actually facilitate pyramidal neuron ﬁring (Ceci
et al., 1999).
Inhibition of ionotropic receptors
Various studies using neuronal preparations from the PFC, the
hippocampus and the rodent globus pallidus have consistently
found that pharmacologicalD4Ractivationdecreases postsynaptic
currents and surface expression of both excitatory and inhibitory
ionotropic receptors (see Tables 1 and 2). GABA current ampli-
tude and surface expression of GABAAR β2/3 clusters are decreased
in PFC pyramidal neurons after treatment with relatively high
concentrations (30 μM) of the D4R agonist PD168077 (Wang
et al., 2002; Graziane et al., 2009). Agonist treatment also reduces
GABAA IPSCs in globus pallidus GABAergic neurons in wild-
type mice but not in Drd4−/− mice (Shin et al., 2003). However,
D4R activation does not affect GABA current amplitude in hip-
pocampal pyramidal neurons during ongoing kainate-induced
oscillations (Andersson et al., 2012a). These data correlate with
the expression of D4Rs on PFC pyramidal and globus pallidus
GABAergic neurons (Mrzljak et al., 1996; Ariano et al., 1997),
but not in hippocampal pyramidal neurons (Andersson et al.,
2012b), and suggest that effects on GABAergic transmission are
cell-autonomous.
D4R stimulation also reduces NMDA and AMPA receptor cur-
rents. NMDA receptor currents and surface expression decrease
in acutely isolated PFC and hippocampal pyramidal neurons in
response to agonist treatment (Kotecha et al., 2002; Wang et al.,
2003; Beazely et al., 2006), although the downstream signaling
pathways may differ between the PFC and hippocampus (see
D4R Signaling Partnerships). Similar effects were reported in pro-
jection neurons of the lateral amygdala (Martina and Bergeron,
2008), and in hippocampal area CA1 where NMDA receptor-
dependent induction of long-term potentiation (LTP) induction
in stratum oriens was inhibited by D4R activation (Herwerth et al.,
2012). Intriguingly, in PFC slices from animals treated with the
NMDA receptor antagonist PCP, a psychotomimetic drug that
in humans can elicit effects remarkably similar to the sympto-
mology of SCZ (Jentsch and Roth, 1999), D4R activation no
longer inhibits NMDA receptor currents, although the cellular
mechanisms underlying this effect are not known (Wang et al.,
2006).
In pyramidal neurons of the PFC, but not the hippocam-
pus, acute D4R activation by low concentrations (100 nM) of
PD168077 was also shown to reduce baseline AMPA receptor cur-
rents and surface expression (Kwon et al., 2008; Yuen et al., 2010;
Andersson et al., 2012a; but see Rubinstein et al., 2001; Gu et al.,
2006). High concentrations of PD168077 also reduce baseline
AMPA receptor currents and surface expression in PFC interneu-
rons (Graziane et al., 2009). Furthermore, recent data suggest that
D4R effects on AMPA receptors may at least in part be state-
dependent. In cultured hippocampal neurons expressing the D4R,
agonist treatment has no effect on baseline AMPA receptor surface
expression but internalizes GluA1-containing AMPA receptors
following a chemical formof LTP (Kwon et al., 2008). In PFC pyra-
midal cells, the D4R agonist PD168077 decreases AMPA currents
when slices are pretreatedwith bicuculline to increase overall activ-
ity by inhibiting GABAA receptors but increases AMPA currents in
slices pretreated with tetrodotoxin (TTX) to reduce overall activ-
ity by inhibiting sodium channels (Yuen et al., 2010; Yuen andYan,
2011). D4Rs also reverse early LTP at Schaeffer collateral-to-CA1
glutamatergic synapses by reversing AMPA receptor-mediated
excitatory postsynaptic currents back to pre-LTP levels (Kwon
et al., 2008). However, in these cases it is not known if this repre-
sents a cell-autonomous or a circuit-based effect. Taken together,
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Table 2 | Presynaptic effects of D4R activation (frequency).
Current Increase/decrease Cell type recorded Region Reference
Glutamate ↓ Pyramidal PFC Rubinstein et al. (2001)
Glutamate No change Interneuron PFC, hippocampus Yuen andYan (2009); Andersson et al. (2012a)
GABA ↓ Various Hypothalamus, septal
nucleus, thalamus
Azdad et al. (2003); Baimoukhametova et al. (2004),
Asaumi et al. (2006); Gasca-Martinez et al. (2010)
with the observation that Drd4−/− mice have dramatic increases
in glutamatergic signaling (Rubinstein et al., 2001), these data sug-
gest that the D4R is involved in homeostatic processes that serve to
maintain overall glutamatergic excitability within a physiological
range.
Effects on ion channels
D4R activation decreases voltage-gated calcium channel currents
in acute PFC slices and cultured cerebellar granule cells (Mei
et al., 1995; Wang et al., 2006). Heterologously expressed D4Rs
also couple to G protein inwardly rectifying potassium channels
in Xenopus oocytes (Werner et al., 1996; Wedemeyer et al., 2007)
through a Gβγ-dependent mechanism (Pillai et al., 1998). In prin-
ciple, both activities are well suited to reduce neurotransmitter
release from presynaptic nerve terminals. Consistent with this
notion, theD4R agonist PD168077 reducesmIPSC frequency onto
layer V pyramidal neurons, indicative of reduced GABA release
from local interneurons (Gao, 2007). Moreover, D4Rs modulate
transmitter release in variousmidbrain regions receivingGABAer-
gic projections from the globus pallidus (Baimoukhametova et al.,
2004; Florán et al., 2004a,b; Asaumi et al., 2006; Acosta-Garcia
et al., 2009; Gasca-Martinez et al., 2010). As mentioned earlier,
globus pallidus GABAergic neurons express high levels of D4R
(Mrzljak et al., 1996). Ablation of globus pallidus neurons by
kainate injection prevents the inhibitory effects of PD168077 in
the thalamic reticular nucleus and the substantia nigra (Acosta-
Garcia et al., 2009; Gasca-Martinez et al., 2010). Effects on
presynaptic calcium currents may also contribute to reduced glu-
tamate release (Rubinstein et al., 2001; Romo-Parra et al., 2005;
Yuen et al., 2010).
D4R SIGNALING PARTNERSHIPS
Dopamine receptors were initially classiﬁed according to their
ability to positively or negatively couple to adenylyl cyclase to
promote the production of the intracellular second messenger
cAMP. Additionally, D2-type receptors mediate many of their
physiological functions via liberation of Gβγ subunits and sub-
sequent modulation of effectors such ion channels and receptors
either by direct binding or by activation of intracellular signaling
pathways such as phospholipase C and mitogen-activated pro-
tein (MAP) kinase. For general reviews on DA signaling pathways
downstream of heterodimeric G proteins the reader is referred to
a number of excellent earlier reviews on the subject (Missale et al.,
1998; Greengard et al., 1999; Gainetdinov et al., 2004; Beaulieu and
Gainetdinov, 2011). In addition, D4Rs have been implicated in a
non-canonical signaling process unique among DA receptors that
involves the stimulation of inherent methyl transferase activity
to modulate phospholipid methylation in response to agonist
treatment (Sharma et al., 1999).
In the current review, we will focus on signaling partnerships
of the D4R with other G protein-coupled receptors (GPCRs) and
with receptor tyrosine kinases (RTK) in the regulation of neuronal
function, as many of the described D4R effects in the central ner-
vous system are tightly linked to the functional association with
other receptor systems. These synergistic partnerships encompass
both direct and functional interactions between receptors.
Partnerships with other G protein-coupled receptors
It is now widely accepted that DA receptors and other GPCRs
can form homomeric and heteromeric structures, and that these
multimeric aggregates can affect both ligand binding as well as
signaling characteristics of their constituent subunits (Ferre et al.,
2007, 2009). Recent studies have shown that the D4R heteromer-
izes with the both the long (D2L) and the short (D2S) forms of the
D2R, alternative splice variants that differ in their third intracel-
lular loop sequence (Borroto-Escuela et al., 2011; Gonzalez et al.,
2012b). Furthermore, neurochemical evidence suggests that inter-
actions between D4 and D2S receptors mediate DA modulation of
neurotransmitter release from corticostriatal glutamatergic pro-
jections where these receptors are co-expressed (Gonzalez et al.,
2012b). Intriguingly, heteromerization with D2S receptors was
observed with D4R variants harboring two or four, but not seven
tandem repeats, and engineered mice with the human 7R ver-
sion knocked into the mouse Drd4 locus failed to show increased
glutamate release in the striatum in response to co-activation of
D2Rs and D4Rs (Gonzalez et al., 2012b). These ﬁndings are espe-
cially relevant in light of the implication of the 7R allele of the
human DRD4 gene in psychiatric disorders. A second interaction
was recently reported between the D4R and α1B or β1 adrenergic
receptors in the pineal gland where these receptors synergize to
regulate circadian melatonin synthesis (Gonzalez et al., 2012a).
Partnerships with receptor tyrosine kinases
Functional interactions between GPCRs and RTKs have been
known for many years (Daub et al., 1996). These interactions are
typically functional, rather than physical, and mostly manifest as
transactivation of a RTK by a GPCR (Ferguson, 2003). An early
example of such transactivation involves the regulation of NMDA
receptors by D4Rs (see Inhibition of Ionotropic Receptors). In
PFC neurons, activation of D4R signaling downregulates NMDA
receptor-mediated synaptic currents and surface expression via
protein kinase A inhibition and activation of protein phosphatase
1, effects typically attributed to canonical inhibitory G protein
signaling (Wang et al., 2003). However, in hippocampal neurons,
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D4R activation downregulates NMDA receptors via transactiva-
tion of the platelet-derived growth factor receptor (PDGFR) and
downstream activation of phospholipase C/inositol triphosphate
(IP3)/Ca2+ signaling (Kotecha et al., 2002). Interestingly, down-
regulation of NMDA receptors in the PFC in response to PDGFR
transactivation by DA is mediated by D2Rs but not D4Rs (Beazely
et al., 2006).
The D4R is also tightly linked to the acute effects of the
NRG-1/ErbB4 signaling pathway in the central nervous system.
Neuregulins comprise a family of secreted and membrane-bound
factors characterized by the presence of an epidermal growth
factor-like motif and that signal through ErbB RTKs to regu-
late a diverse array of developmental and acute processes in the
peripheral and central nervous systems (Garratt et al., 2000; Buo-
nanno and Fischbach, 2001; Falls, 2003). Moreover, both NRG1
and ERBB4 have been identiﬁed as risk genes for SCZ (Mei and
Xiong, 2008). NRG-1/ErbB4 signaling inhibits the induction and
reverses the early expression of LTP at CA3 to CA1 glutamater-
gic synapses (Huang et al., 2000; Kwon et al., 2005; Shamir et al.,
2012). LTP reversal by NRG-1 critically depends on the activation
of D4Rs (Kwon et al., 2008). Taken together with the ﬁnding that
NRG-1 infusion in the dorsal hippocampus triggers DA release,
this suggests that NRG-1/ErbB4 signaling regulates hippocampal
LTP via a DA/D4R pathway (Kwon et al., 2008). However, it is
not known if these receptor systems interact in the same or across
different cell types, or which signaling pathways link their activa-
tion to the removal of synaptic AMPA receptors that underlie LTP
reversal by NRG-1 and D4R agonists. For the following reasons,
a direct effect on PV interneurons is more likely than on pyrami-
dal neurons: (1) ErbB4 receptors are undetectable in pyramidal
neurons (Vullhorst et al., 2009; Neddens et al., 2011) while both
ErbB4 and D4Rs are expressed in GABAergic cells including PV
interneurons (Mrzljak et al., 1996; Andersson et al., 2012b). (2)
Inhibition of LTP induction and reversal of LTP are absent from
mice with targeted deletions of ErbB4 in PV interneurons (Chen
et al., 2010; Shamir et al., 2012); (3) Both receptors also appear to
synergize in the modulation of hippocampal gamma oscillations
that critically depend on PV interneurons (see D4R and Gamma
Oscillations for details).
D4R AND GAMMA OSCILLATIONS
Two lines of evidence suggested a possible role for the D4R in
the regulation of hippocampal gamma oscillations. First, many
PV interneurons contain D4R mRNA and protein (see Expres-
sion in FS Parvalbumin Interneurons). Second, earlier studies
in acute rodent slices showed that NRG-1 signaling via ErbB4
potently augments kainate-induced gamma oscillations in hip-
pocampal area CA3 (Fisahn et al., 2009). Taken together with the
ﬁnding that NRG-1/ErbB4 effects on LTP reversal in CA1 critically
depend on D4R signaling (see Partnerships with Receptor Tyro-
sine Kinases), it was plausible to hypothesize that NRG-1 effects
on gamma oscillation power also depend on D4R signaling (see
Buonanno, 2010). Indeed, the D4R antagonist L-745,870 largely
blocks the potentiating effects of NRG-1 on gamma oscillations
(Andersson et al., 2012b). Conversely, the D4R agonist PD168077
increases gamma power, albeit to a lesser extent than ErbB4 acti-
vation by NRG-1, suggesting that NRG-1/ErbB4 signaling engages
multiple signaling systems that synergistically augment gamma
oscillations. Neither PD168077 nor NRG-1 induce gamma oscil-
lations in naïve slices, indicating that their modulatory effects
impinge on ongoing oscillations (Fisahn et al., 2009; Andersson
et al., 2012b). An investigation into the cellular effects of D4R
signaling revealed that PD168077 enhances spike coherence and
phase-coupling of action potentials relative to gamma cycle in FS
interneurons, suggesting that D4R activation enhances gamma
power by augmenting the synchronized inhibition of pyramidal
neurons (Andersson et al., 2012a). Notably, pharmacological acti-
vation of other DA receptors, or direct application of DA, had
no effect on gamma power. However, an enhancement of gamma
power by DA was unmasked by simultaneous application of the
D1-type receptor blocker SCH23390, indicating that D1-type DA
receptors antagonize the effects of D4Rs on gamma oscillations
(Andersson et al., 2012b).
Interestingly, D4R-mediated augmentation of gamma power
is sensitive to pharmacological blockade of NMDA receptors by
AP5 (D-2-amino-5-phosphonopentanoate), although AP5 has no
effect on gamma power per se (Andersson et al., 2012b). Given that
D4Rs internalize NMDA receptors (see Inhibition of Ionotropic
Receptors), a simple explanation might be that D4R activation
improves excitation-spiking coupling by removing NMDA recep-
tors from excitatory synapses of FS interneurons to increase
gamma power. Indeed, blockade of NMDA receptors increases
gamma power in vivo (Pinault, 2008). Yet, if this were true, block-
ing NMDA receptors would occlude rather than inhibit the D4R
effect on gamma power, and would increase gamma power even
in the absence of D4R agonist. However, as mentioned earlier, this
was not observed in vitro (Andersson et al., 2012a). At this time, the
relationship between D4R signaling and NMDA receptor function
in kainate-induced hippocampal oscillations is therefore unclear.
Studies exploring the role of D4Rs in gamma oscillations in
the PFC are currently lacking. Considering the conserved expres-
sion of D4Rs and ErbB4 receptors in PV interneurons in the
hippocampus and neocortex, it is reasonable to speculate that
synergistic signaling downstream of both signaling pathways also
modulates neocortical gamma rhythms. On the other hand, there
are signiﬁcant differences between the hippocampus and the PFC.
For example, D4R activation reduces NMDA currents via PDGFR
transactivation in the hippocampus and via canonical Gai signal-
ing the PFC (see Partnerships with Receptor Tyrosine Kinases).
Furthermore, D4Rs in the PFC are expressed on both interneu-
rons and pyramidal neurons, while in the hippocampus pyramidal
neurons mostly do not express the receptor (see Expression in FS
Parvalbumin Interneurons). However, indirect evidence already
exists that D4Rs in the human cortex modulate gamma oscilla-
tions. Carriers of the 7R DRD4 allele (DRD4.7) show enhanced
evoked and induced gamma oscillations in the frontal and asso-
ciation cortices in response to auditory stimuli (Demiralp et al.,
2007). This increase in evoked gamma oscillations does not dis-
criminate between target and ﬁller stimuli, suggesting that it is
harder for subjects to distinguish between salient and distract-
ing stimuli, a ﬁnding that is consistent with the association of
the DRD4.7 allele with ADHD and potentially cognitive function
in other psychiatric disorders (see Pharmacological Properties and
Involvement in Psychiatric Disorders). Importantly, the 7R variant
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has half the potency of more common third-loop repeat vari-
ants for inhibiting cAMP (Asghari et al., 1995) and less effectively
forms heterodimers with the long and short variants of the D2R
(Borroto-Escuela et al., 2011; Gonzalez et al., 2012b). If the mod-
ulation of gamma rhythms in individuals carrying the DRD4.7
polymorphism is indeed compromised, the prediction would be
that normal D4R function enhances signal-to-noise ratios by
suppressing gamma rhythms in response to non-salient sensory
stimuli. At least in principle, the ﬁnding that D4Rs decrease
AMPA currents in interneurons in the PFC (Yuen and Yan, 2009),
and that decreased excitatory drive onto PV interneurons reduces
gamma oscillation power (Rotaru et al., 2011), correlates well with
increases in gamma in subjects carrying the DRD4.7 allele.
OUTLOOK
The association of gamma oscillations with attention, working
memory and other cognitive functions, and their perturbation in
numerous psychiatric disorders, underscores the potential ther-
apeutic value of targeting networks that generate and regulate
gamma oscillations (see Andersson et al., 2012b). Based on work
reviewed herein, we propose that a potential functional role for
DA in modulating cognitive processes is through opposing effects
onneuronal excitability, synaptic strength, and gammaoscillations
mediated via D1- andD2-typeDA receptors (see Kwon et al., 2008;
Andersson et al., 2012b). Consequently, the regional and temporal
dynamic changes of DA concentrations in the hippocampus and
PFC could determine the D1-/D2-type receptor activity ratio that
ultimately modulates gamma oscillation power and synchrony at
rest (baseline) and evoked by salient stimuli; the relative activity of
both receptor types could account for the invertedU-shaped dose–
response relationship associatedwithDAeffects. TheD1-/D2-type
receptor activity ratio is especially important for the regulation of
GABAergic function in the PFC (Seamans et al., 2001; Goldman-
Rakic et al., 2004; Trantham-Davidson et al., 2004; Enomoto
et al., 2011), where excitatory/inhibitory balance is critical for
the optimization of cognitive task performance and ﬂexibility
(Winterer and Weinberger, 2004). Because optimal signal-to-
noise ratio of cortical microcircuits is important for cognitive
tasks (Winterer and Weinberger, 2004), and alterations in gamma
frequency oscillations are associated with psychiatric disorders
(Herrmann and Demiralp, 2005; Uhlhaas and Singer, 2010), iden-
tifying modulators that improve signal-to-noise ratio by targeting
cortical microcircuits could constitute a promising therapeutic
approach.
We propose, based on the functional properties and expression
of ErbB4 and D4Rs in GABAergic PV-expressing interneurons in
the DLPFC (Mrzljak et al., 1996) and hippocampus (Andersson
et al., 2012b), as well as their effects on kainate-induced gamma
oscillations and plasticity (Kwon et al., 2008), that these receptors
are well situated to modulate network activity that affects cogni-
tion (see Partnerships with Receptor Tyrosine Kinases, and D4R
and Gamma Oscillations). Although D4R-speciﬁc antagonists
were found to be ineffective as antipsychotics for the treatment
of SCZ (see Pharmacological Properties and Involvement in Psy-
chiatric Disorders), D4R-targeting drugs still hold potential as
adjunct therapies to ameliorate the cognitive deﬁcits seen in SCZ
(see Andersson et al., 2012b). The fact that D4R activity can reg-
ulate working memory and other cognitive behaviors in rodent
models (Zhang et al., 2004; Braszko, 2009; Young et al., 2011), and
that their effects are state-dependent (Zhang et al., 2004), suggests
that D4R modulators could be used to modulate D1-/D2-type
receptor ratio and improve signal-to-noise ratio. Given that the
cognitive responses to D4R-targeting drugs depend on emotional
salience and baseline ability that may easily reﬂect basal DA con-
centration, it is plausible that people with different variants of the
D4R may respond differently to these therapies. D4R agonists may
prove more efﬁcacious in some patients, while D4R antagonists
may prove more efﬁcacious in others, and oscillatory activity may
help predict which therapy will be more effective.
While pharmacological targeting of D4Rs for regulating net-
work activity and cognitive function appears to be a promising
approach, as we have elaborated throughout this review, one must
be mindful of the many complexities of D4R signaling when
designing and interpreting meaningful experiments for future
studies. These considerations include the likelihood that the cel-
lular D4R expression pattern varies in different cortical regions,
that drug effects on D4R function might be dose-dependent and
that the receptor might engage in distinct signaling partnerships
in different cells or subcellular compartments. The challenge will
therefore be to ﬁnd among the abundance of possibilities the ones
that are pertinent to the regulation of local circuit activity and their
potential to improve cognitive processes deﬁcient in a number of
neurological and psychiatric disorders. Perhaps treatments tai-
lored to increase or reduce D4R activity in different patients holds
promise for approaches that for the past decades have failed to
improve working memory and other cognitive functions in these
disorders (see Insel, 2010).
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